Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Board Nominations at Vermillion and More

Premium

Vermillion has nominated Paul Sohmer to stand for election to its board of directors at the company's upcoming board meeting.

Sohmer is CEO of Viracor-IBT Laboratories. He formerly was CEO of Pathway Diagnostics, Orthocon, and Cylex, and he was chairman of Molecular Biometrics. He also was CEO, chairman, and president at TriPath Imaging and Neuromedical Systems.


Quintiles this week named Tom Pike as CEO, replacing company founder Dennis Gillings, who will continue as executive chairman of the company's board of directors.

Pike worked at Accenture until 2010 where he held a number of roles including global chief operating officer for the company's resources operating group. Since leaving Accenture he has been involved in several technology and healthcare startups.


Morphosys has nominated Karin Eastham and Marc Cluzel as members of the company's supervisory board.

Eastham is director of several corporate boards including Illumina, Amylin, Trius Therapeutics, and Geron. Cluzel is the executive vice president of product development at HUYA Bioscience as well as the founder of C&F Consulting.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.